Clinical lung cancer
Clinical Lung Cancer is an Elsevier journal for clinical and translational lung cancer research, from screening and diagnosis to drug resistance and multimodality treatment. Thoracic oncologists and lung cancer researchers read it.
Overview
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles on clinical and translational research in lung cancer, devoted to detection, diagnosis, prevention and treatment with emphasis on recent scientific developments. Its stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention strategies, multimodality therapy and integration of approaches. ScienceDirect lists the journal as supporting open access, meaning authors may choose open access or subscription publication. NLM records the title from 1999, first published in Dallas by the Cancer Information Group and from 2011 by Elsevier in New York, bimonthly since July 2002, indexed in MEDLINE and PubMed. Not listed in DOAJ.
Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.
Lung cancer specialist at Wakayama Medical University who chairs the West Japan Oncology Group cooperative trials network.
Pages like this
not linked directly; found by shared links- JournalZhongguo fei ai za zhi
Shares Small-cell lung cancer, PubMed & Europe PMC, Non-small-cell lung cancer.
- JournalThoracic cancer
Shares Small-cell lung cancer, PubMed & Europe PMC, Non-small-cell lung cancer.
- InstitutionWest Japan Oncology Group
Shares Nobuyuki Yamamoto, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonMartin Schuler
- PersonCaicun Zhou
- PersonShun Lu
- PersonAlexis Cortot
- JournalLung cancer
Shares Small-cell lung cancer, PubMed & Europe PMC, Non-small-cell lung cancer.